Diamedica Therapeutics Inc (DMAC) Stock Price, Quote & News

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulin...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 496 5454

Website: www.diamedica.com

Address:

301 Carlson Parkway, Suite 210, Minneapolis, United States

alexpitti Jun. 3 at 6:55 PM

We met with management ceo and cfo today for lunch $DMAC

3 · Reply

SuperGreenToday Jun. 3 at 11:22 AM

$DMAC Share Price: $5.78 Contract Selected: Jan 15, 2027 $7.5 Calls Buy Zone: $1.19 – $1.47 Target Zone: $2.10 – $2.56 Potential Upside: 66% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

alexpitti Jun. 1 at 9:08 PM

in the next 2 weeks i'm talking to ceos of $DCTH $RCEL $DMAC likely $LRMR and sophrosyne which is a private company

2 · Reply

JMforProfits May. 26 at 2:16 PM

$DMAC Billionaire investor Leon Cooperman owns shares of DMAC. Recent SEC filings show he owns roughly 3.45 million shares, representing about 6.6% of the company through personal holdings and the Leon & Toby Cooperman Foundation.

0 · Reply

JMforProfits May. 26 at 1:50 PM

$DMAC

0 · Reply

DARKP00L May. 20 at 12:57 PM

$DMAC 08:38 on May. 20 2026 DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke #tradeideas

0 · Reply

Stock_picker_trader May. 15 at 8:31 PM

$DMAC Leon Cooperman is still in and avoided selling out when it went over 10. He’s looking for it to go above that level it seems.

0 · Reply

Stock_picker_trader May. 7 at 9:37 PM

$DMAC now til Q1 2027 is gonna get exciting. This company is starting to pick up steam now. Nice questions from analysts on the call today.

0 · Reply

Pegger May. 7 at 8:23 PM

$DMAC I guess it’s not just me, but it felt like someone was accumulating shares today

0 · Reply

Sukitt May. 7 at 7:20 PM

$DMAC Today should be seen as a gift. 🎁 💎💪🏻

0 · Reply

DiaMedica Therapeutics Slides: Corporate presentation

May 27, 2026, 4:30 PM EDT - 8 days ago

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

2026-05-20T12:41:03.000Z - 15 days ago

DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial

May 20, 2026, 8:30 AM EDT - 15 days ago

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

May 12, 2026, 4:15 PM EDT - 23 days ago

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 7, 2026, 8:00 AM EDT - 4 weeks ago

DiaMedica Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 weeks ago

DiaMedica Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 weeks ago

DiaMedica Therapeutics Quarterly report: Q1 2026

2026-05-07T01:03:34.000Z - 4 weeks ago

DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)

May 6, 2026, 4:30 PM EDT - 4 weeks ago

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Apr 30, 2026, 8:25 AM EDT - 5 weeks ago

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

Apr 16, 2026, 11:00 AM EDT - 7 weeks ago

DiaMedica Therapeutics Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 7, 2026, 7:00 AM EDT - 2 months ago

DiaMedica Therapeutics Slides: Corporate presentation

Apr 1, 2026, 8:00 AM EDT - 2 months ago

DiaMedica Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 2 months ago

DiaMedica Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

DiaMedica Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 2 months ago

DiaMedica Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 2 months ago

DiaMedica Therapeutics Earnings release: Q4 2025

2026-03-30T20:50:55.000Z - 2 months ago

DiaMedica Therapeutics reports FY25 EPS (70c), consensus (68c)

Mar 30, 2026, 4:45 PM EDT - 2 months ago

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Mar 23, 2026, 8:25 AM EDT - 2 months ago

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

2026-03-05T12:59:38.000Z - 3 months ago

DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study

Mar 5, 2026, 7:35 AM EST - 3 months ago

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

Mar 2, 2026, 6:00 AM EST - 3 months ago

DiaMedica Therapeutics Slides: Corporate presentation

Feb 24, 2026, 9:23 AM EST - 3 months ago

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

Jan 16, 2026, 5:00 PM EST - 4 months ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-05T13:46:27.000Z - 5 months ago

DiaMedica Therapeutics named a Top Idea for 2026 at Lake Street

2025-12-18T14:16:01.000Z - 6 months ago

DiaMedica Therapeutics provides DM199 update following FDA meeting

Dec 18, 2025, 8:45 AM EST - 6 months ago

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

2025-11-14T13:10:30.000Z - 7 months ago

DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-11-14T11:20:28.000Z - 7 months ago

DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald

Nov 13, 2025, 8:00 AM EST - 7 months ago

DiaMedica Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

DiaMedica Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

DiaMedica Therapeutics Earnings release: Q3 2025

2025-11-12T21:35:21.000Z - 7 months ago

DiaMedica Therapeutics reports Q3 EPS (17c), consensus (16c)

Nov 12, 2025, 4:30 PM EST - 7 months ago

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 10, 2025, 8:15 AM EST - 7 months ago

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:15 PM EST - 7 months ago

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

2025-10-30T11:07:26.000Z - 7 months ago

DiaMedica Therapeutics initiated with a Buy at TD Cowen

Sep 29, 2025, 4:15 PM EDT - 8 months ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Sep 5, 2025, 8:30 AM EDT - 9 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

Sep 4, 2025, 9:10 AM EDT - 9 months ago

DiaMedica Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 8:23 AM EDT - 9 months ago

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Earnings release: Q2 2025

2025-08-12T21:15:22.000Z - 10 months ago

DiaMedica Therapeutics files $100M mixed securities shelf

2025-08-12T20:20:17.000Z - 10 months ago

DiaMedica Therapeutics reports Q2 EPS (18c), consensus (19c)

Aug 12, 2025, 4:15 PM EDT - 10 months ago

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Registration statement: Registration Filing

2025-08-06T13:35:30.000Z - 10 months ago

DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds

Aug 6, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Aug 5, 2025, 4:15 PM EDT - 10 months ago

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

2025-08-01T12:36:24.000Z - 10 months ago

DiaMedica Therapeutics files to sell 8.61M common shares for holders

Aug 1, 2025, 8:00 AM EDT - 10 months ago

DiaMedica Therapeutics Registration statement: Registration Filing

Jul 23, 2025, 4:30 PM EDT - 11 months ago

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

2025-07-21T13:20:10.000Z - 11 months ago

DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

Jul 21, 2025, 8:00 AM EDT - 11 months ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

2025-07-18T13:00:18.000Z - 11 months ago

DiaMedica Therapeutics price target raised to $11 from $8 at Craig-Hallum

2025-07-18T12:40:25.000Z - 11 months ago

DiaMedica Therapeutics price target raised to $14 from $11 at Lake Street

Jul 17, 2025, 4:30 PM EDT - 11 months ago

DiaMedica Therapeutics Transcript: Study Result

Jul 17, 2025, 4:30 PM EDT - 11 months ago

DiaMedica Therapeutics Press release: Study Result

Jul 17, 2025, 4:30 PM EDT - 11 months ago

DiaMedica Therapeutics Slides: Study Result

Jul 17, 2025, 8:00 AM EDT - 11 months ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 28, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Transcript: Status Update

May 28, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Slides: Status Update

May 22, 2025, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 20, 2025, 3:30 PM EDT - 1 year ago

DiaMedica Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 9:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 8, 2025, 4:00 PM EDT - 1 year ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 7, 2025, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Mar 28, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Proxy statement: Proxy Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings release: Q4 2024

Mar 17, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 11, 2025, 8:23 AM EDT - 1 year ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Feb 24, 2025, 8:30 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 20, 2025, 8:15 AM EST - 1 year ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 10, 2025, 4:15 PM EST - 1 year ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 8:00 AM EST - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

DiaMedica Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 4:20 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 8, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 2 years ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 10, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Registration statement: Registration Filing

Jul 1, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 27, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Transcript: Status Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Press release: Status Update

Jun 27, 2024, 7:00 AM EDT - 2 years ago

DiaMedica Therapeutics Slides: Corporate Presentation

Jun 26, 2024, 8:15 AM EDT - 2 years ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 9, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Quarterly report: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics Earnings release: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 8:55 AM EDT - 2 years ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

alexpitti Jun. 3 at 6:55 PM

We met with management ceo and cfo today for lunch $DMAC

3 · Reply

SuperGreenToday Jun. 3 at 11:22 AM

0 · Reply

alexpitti Jun. 1 at 9:08 PM

in the next 2 weeks i'm talking to ceos of $DCTH $RCEL $DMAC likely $LRMR and sophrosyne which is a private company

2 · Reply

JMforProfits May. 26 at 2:16 PM

0 · Reply

JMforProfits May. 26 at 1:50 PM

$DMAC

0 · Reply

DARKP00L May. 20 at 12:57 PM

$DMAC 08:38 on May. 20 2026 DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke #tradeideas

0 · Reply

Stock_picker_trader May. 15 at 8:31 PM

$DMAC Leon Cooperman is still in and avoided selling out when it went over 10. He’s looking for it to go above that level it seems.

0 · Reply

Stock_picker_trader May. 7 at 9:37 PM

$DMAC now til Q1 2027 is gonna get exciting. This company is starting to pick up steam now. Nice questions from analysts on the call today.

0 · Reply

Pegger May. 7 at 8:23 PM

$DMAC I guess it’s not just me, but it felt like someone was accumulating shares today

0 · Reply

Sukitt May. 7 at 7:20 PM

$DMAC Today should be seen as a gift. 🎁 💎💪🏻

0 · Reply

StocktwitsEarnings May. 7 at 10:00 AM

$DMAC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 down -5.56% YoY • DiaMedica Therapeutics Inc. expects to incur substantial operating losses and negative cash flows, anticipated to moderately increase due to ongoing DM199 clinical development. Current cash resources are sufficient for planned operations for at least the next 12 months.

0 · Reply

Relee187200 May. 6 at 11:49 PM

$DMAC Why no reaction to earnings?

0 · Reply

MedCred Apr. 27 at 12:57 PM

$DMAC stroke trial should be close to 150. Or even 160. I’d think recruitment at least 10-20 per month. 63 sites. Would be nice to hear something about pace of enrollment.

0 · Reply

Stock_picker_trader Apr. 16 at 7:26 PM

$DMAC if after the interim analysis of stroke continues it would take the following quarter for enrollment to be complete

1 · Reply

Relee187200 Apr. 15 at 2:40 AM

$DMAC Big down after hours

0 · Reply

RealAvidTrader Apr. 13 at 7:49 PM

$DMAC Very Small Add - Buy Alert in Our Group $5.78 (Post in Comments Below) - Dipped Off No News, No Real Reason To Be Down. Love It Under $6.00 as Short Term (Temporary Bottom) https://youtu.be/CSd0b1RGuh0

1 · Reply

Relee187200 Apr. 8 at 7:35 PM

$DMAC Why down so much today?

2 · Reply

garrstev88 Apr. 8 at 8:24 AM

$DMAC calm post-market with balanced liquidity If bids fail to hold, price may stall and enter sideways chop

0 · Reply

RealAvidTrader Apr. 7 at 12:54 PM

$DMAC The Best $6 Stock Setup? (Deep Dive Analysis) https://youtu.be/CSd0b1RGuh0

0 · Reply

TalkMarkets Apr. 1 at 1:21 AM

DiaMedica Therapeutics Closes 2025 With Strengthened Cash Position And Pipeline Momentum $DMAC https://talkmarkets.com/article/diamedica-therapeutics-closes-2025-with-strengthened-cash-position-and-pipeline-momentum-1775006375

1 · Reply

Stock_picker_trader Apr. 1 at 12:41 AM

$DMAC Dm199 KOL manuscript https://d1io3yog0oux5.cloudfront.net/_2a43f49bcff7dd6b6016aa912d2127c0/diamedica/db/197/3305/presentation/%5BCall+Transcript%5D+KOL+Webinar+Highlights+DM-199+For+Pre-Eclampsia+Looks+Like+a+Real+Drug.pdf

0 · Reply

Market Cap	304.44M
Revenue (ttm)	0.00
Net Income (ttm)	-32.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	93,400
Avg Vol	177,002
Day's Range	N/A - N/A
Shares Out	53.88M
Stochastic %K	33%
Beta	0.97
Analysts	Strong Sell
Price Target	$15.50